Clinical trials: Hematologic Cancer
Relapsed/Refractory Multiple Myeloma
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
This is an investigator-initiated, single-center, early-phase clinical study comprising dose escalation and dose expansion phases, designed to evaluate the safety and efficacy of IMV102 in subjects with relapsed/refractory…
- Trial name
- NCT07493135
- Testing
- IMV102 treatment
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- Suzhou Immunofoco Biotechnology Co., Ltd
Hematologic Malignancy
Prospective Cohort With Hemopathy in Languedoc-Roussillon
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.
- Trial name
- HemoDiag (NCT02134574)
- Testing
- hematologic malignancy
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Montpellier
Myelodysplastic Syndromes (MDS), Beta-thalassemia
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: Participants receiving luspatercept on a parent protocol at the time of their transition to the…
- Conditions
- Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
- Trial name
- NCT04064060
- Testing
- Luspatercept
- Where
- 143 sites in United States, Australia and 20 more
- Volunteers
- 665 people
- Sponsor
- Celgene
Chronic Lymphoid Leukemia
The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases
Recent data have shown that the inadequate vitamin D status plays a role in the manifestation of the haematologic tumors and serum vitamin D level has a prognostic role also as it determines the tumor mortality.
- Trial name
- D-HEM (NCT01518959)
- Testing
- Cholecalciferol, oleum neutralicum
- Where
- Hungary
- Volunteers
- 31 people
- Sponsor
- Semmelweis University
Gastrointestinal Cancer, Hematologic Cancer
SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
SURGE aims to increase representation in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies.
- Conditions
- Gastrointestinal Cancer, Hematologic Cancer, Thoracic Cancer
- Trial name
- SURGE (NCT05375643)
- Testing
- SURGE
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Nadine Jackson, MD, MPH
Acute Promyelocytic Leukemia
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
This is a Phase II, open-label, non-randomized study to evaluate the safety, efficacy, and pharmacokinetics of tamibarotene in adult patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with…
- Trial name
- STAR-1 (NCT00520208)
- Testing
- Tamibarotene
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- CytRx
Multiple Myeloma
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome function, promotes accumulation of cytotoxic misfolded protein aggregates and triggers myeloma cell…
- Trial name
- PANORAMA-1 (NCT01023308)
- Testing
- Panobinostat, Bortezomib, Dexamethasone
- Where
- 210 sites in United States, Argentina and 32 more
- Volunteers
- 767 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia
A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)
The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients.
- Trial name
- NCT00073489
- Testing
- OSI-461
- Where
- 15 sites in United States
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Inc
Haematological Malignancy, Bone Marrow Transplant Complications
Nutrition and Metabolic Prehabilitation in HSCT Patients UK and ROI. BSBMT Multi-centre Survey.
To explore current practices of nutrition and metabolic screening, assessment and management prior to Haematopoietic Stem Cell Transplant (HSCT) in UK and ROI transplant centres.
- Conditions
- Haematological Malignancy, Bone Marrow Transplant Complications, Stem Cell Transplant Complications, Nutrition Aspect of Cancer
- Trial name
- NCT05352789
- Testing
- Non validated Survey
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Nottingham University Hospitals NHS Trust
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
This phase II MATCH treatment trial identifies the effects of trametinib in patients whose cancer has a has a genetic change called NF1 mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439318
- Testing
- Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphocytic Leukemia, Lymphoma
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
The purpose of this study is to test the safety of giving the patient special cells from a donor called "Modified T-cells". The goal is to assess the toxicities of T-cells for patients with relapsed B cell leukemia or lymphoma…
- Trial name
- NCT01430390
- Testing
- Biological/Genetically Modified T cells, Cyclophosphamide-based chemotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Background: Several types of blood cancer are associated with poor outcomes including high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myelogenous leukemia (AML).
- Conditions
- Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia, Bone Marrow Diseases, Neutropenia
- Trial name
- NCT01629082
- Testing
- Clofarabine, Lenalidomide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cancer, Solid Tumor
Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies
This is an investigator-initiated, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of Erythrocyte-αPD-1 conjugates in patients with advanced malignancies
- Conditions
- Cancer, Solid Tumor, Hematologic Malignancy
- Trial name
- NCT06528249
- Testing
- Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
- Volunteers
- 39 people
- Sponsor
- Zhejiang Provincial People's Hospital
Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
This phase II trial studies how well anti-cluster of differentiation (CD)19 monoclonal antibody MOR00208 and lenalidomide work in treating patients with relapsed, refractory, or previously untreated chronic lymphocytic leukemia…
- Conditions
- Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
- Trial name
- NCT02005289
- Testing
- MOR00208, lenalidomide, Correlative Studies
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid…
- Conditions
- Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome
- Trial name
- NCT00801489
- Testing
- Cytarabine, Decitabine, Filgrastim-sndz
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma or Amyloidosis
Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System
This study is evaluating a new method for administering daratumumab, a treatment commonly used in the management of multiple myeloma and amyloidosis.
- Trial name
- ESCAPE (NCT07721350)
- Testing
- Subcutaneous Daratumumab Administration Using FreedomEDGE®
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Gastrointestinal Cancer, Breast Cancer
Feasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (PAMCaP)
This is an open label feasibility pilot study of commercially available physical activity monitoring devices in patients receiving systemic therapy at the Harold Simmons Cancer Center, UT Southwestern Medical Center.
- Conditions
- Gastrointestinal Cancer, Breast Cancer, Gynecologic Cancer, Genitourinary Cancer
- Trial name
- PAMCap (NCT02583815)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Texas Southwestern Medical Center
Stem Cell Transplantation
Adherence, Viability, Clinical Evolution and Therapeutic Efficacy in Patients Undergoing Bone Marrow Transplantation
Hematological neoplasms originate from the differentiation and proliferation of abnormal lymphatic or myeloid cells that alter the constitution of elements of the blood, bone marrow and lymph nodes.
- Trial name
- NCT06134297
- Testing
- Cycle ergometer, Strength Training - elastic band and shin guards, Cycle ergometer, elastic band and shin guards
- Where
- Brazil
- Volunteers
- 93 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Childhood Cancer
Strength Training and ADLs in Childhood Leukemia and Lymphoma Patients
Reduced activity levels and reduced muscular strength could severely impair the activities of daily living (ADLs) in pediatric leukemia and Non-Hodgkin lymphoma patients.
- Trial name
- NCT03934060
- Testing
- Exercise
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Technical University of Munich
Anemia, Carcinoma, Non-Small-Cell Lung
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
The purpose of this study was to determine an effective and safe dose of sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia (CIA) in participants with metastatic non-small cell lung cancer (NSCLC) who are…
- Conditions
- Anemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small-Cell Lung, Bladder Cancer
- Trial name
- NCT01284348
- Testing
- Sotatercept 15 mg, Sotatercept 30 mg
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC